These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7368144)

  • 1. In vitro thrombogenicity tests of factor IX concentrates. II: effects of phospholipids and heparin.
    Prowse CV; Boffa MC; Guthrie C; Pepper DS
    Thromb Haemost; 1980 Feb; 42(5):1368-77. PubMed ID: 7368144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro thrombogenicity tests of factor IX concentrates. I. A survey of available assays.
    Prowse CV; Chirnside A; Elton RA
    Thromb Haemost; 1980 Feb; 42(5):1355-67. PubMed ID: 6768149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the in vitro and in vivo thrombogenic activity of factor IX concentrates using stasis (Wessler) and non-stasis rabbit models.
    Prowse CV; Williams AE
    Thromb Haemost; 1980 Oct; 44(2):81-6. PubMed ID: 6779401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing for potential thrombogenicity of prothrombin complex concentrates.
    Snape TJ
    Dev Biol Stand; 1979; 44():199-204. PubMed ID: 544295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentially thrombogenic materials in factor IX concentrates.
    Kingdon HS; Lundblad RL; Veltkamp JJ; Aronson DL
    Thromb Diath Haemorrh; 1975 Jun; 33(3):617-31. PubMed ID: 1154317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrophotometric determination of factor Xa generation in factor IX concentrates.
    Pepper DS; Banhegyi D; Howie A
    Thromb Haemost; 1977 Jun; 37(3):535-40. PubMed ID: 578033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
    Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
    J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (Factor IX) concentrates in rabbits.
    Giles AR; Nesheim ME; Hoogendoorn H; Tracy PB; Mann KG
    Blood; 1982 Feb; 59(2):401-7. PubMed ID: 7034817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro investigation of prothrombin complex concentrates.
    Römisch J; Bonik K; Müller HG
    Semin Thromb Hemost; 1998; 24(2):175-81. PubMed ID: 9579640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo.
    White GC; Roberts HR; Kingdon HS; Lundblad RL
    Blood; 1977 Feb; 49(2):159-70. PubMed ID: 12845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity.
    MacGregor IR; Ferguson JM; McLaughlin LF; Burnouf T; Prowse CV
    Thromb Haemost; 1991 Nov; 66(5):609-13. PubMed ID: 1803625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity.
    Gray E; Tubbs J; Thomas S; Oates A; Boisclair M; Kemball-Cook G; Barrowcliffe TW
    Thromb Haemost; 1995 Apr; 73(4):675-9. PubMed ID: 7495077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding to phospholipid protects factor VIII from inactivation by human antibodies.
    Barrowcliffe TW; Kemball-Cook G; Gray E
    J Lab Clin Med; 1983 Jan; 101(1):34-43. PubMed ID: 6401316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thrombin formation in factor IX concentrates and FEIBA (factor eight inhibitor bypassing activity) (proceedings)].
    Hofmann V; Ermanni M; Straub PW
    Schweiz Med Wochenschr; 1978 Oct; 108(41):1600. PubMed ID: 694497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
    Meddahi S; Bara L; Fessi H; Samama MM
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic ATIII-binding pentasaccharide.
    Lormeau JC; Herault JP
    Thromb Haemost; 1993 Feb; 69(2):152-6, 176. PubMed ID: 8384381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma.
    Ofosu FA; Lormeau JC; Craven S; Dewar L; Anvari N
    Thromb Haemost; 1994 Dec; 72(6):862-8. PubMed ID: 7740455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prothrombin complex concentrates.
    Penner JA
    Bibl Haematol; 1977; 44():81-7. PubMed ID: 617787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A test method for the absence of thrombogenicity in factor IX complex.
    Miura Y; Abe T; Kazama M; Yasuda J
    Dev Biol Stand; 1979; 44():189-97. PubMed ID: 544293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.